Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2018-07-30 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于控股股东部分股份解除质押的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement from a company about the partial release of pledged shares by its controlling shareholder. It details the number of shares released from pledge, remaining pledged shares, dates, and related parties. There is no financial report, earnings data, or management discussion. The content is about a change in share pledge status, which relates to shareholding and capital structure but is not a capital raising or new share issuance event. It is not a report or presentation but an announcement of a transaction involving shares. This fits best under 'Transaction in Own Shares' (POS) as it involves the company's shares being released from pledge, which is a form of share transaction disclosure. The document length is short and focused on this specific transaction, not a broader report or regulatory filing. Therefore, the classification is POS with high confidence.
2018-07-30 Chinese
关于使用部分闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhuhai Jianfan Biotechnology Co., Ltd. regarding the progress of cash management using part of its idle own funds. It details the purchase of financial products, investment risks, risk mitigation measures, and the impact on the company. It also lists the main financial products purchased in the past twelve months. The document references previous shareholder meeting resolutions and related contracts. There is no indication that this is a full financial report, audit report, or earnings release. It is a regulatory announcement about the company's capital management activities, specifically cash management and investment of idle funds. This fits best under Capital/Financing Update (CAP) as it relates to updates on company financing activities and capital usage. The document length is over 5,000 characters and contains substantive information, not just a notice or certification, so it is not RPA or RNS.
2018-07-11 Chinese
关于“健帆HA130血液灌流器联合血液透析改善维持性血液透析患者生存质量前瞻、随机、对照的多中心临床研究”成果发布会的公告
Regulatory Filings Classification · 90% confidence The document is a public announcement by Zhuhai Jianfan Biotechnology Co., Ltd. regarding the results release of a multi-center randomized controlled clinical trial (RCT) involving their HA130 blood perfusion device. It details the study design, participating institutions, patient numbers, and key conclusions of the clinical research. The document is an announcement of the clinical study results and the related event (成果发布会 - results release meeting) held on July 5, 2018. It does not contain financial statements, audit opinions, or detailed financial data. The document length is 2711 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication that this is an Annual Report, Interim Report, Earnings Release, or any other financial filing. It is also not a regulatory filing or management change announcement. The content focuses on the clinical study results and their impact on the company’s product and market position, which aligns with an Investor Presentation or a similar disclosure. However, since it is a formal public announcement of the clinical study results event rather than a detailed investor presentation document, the best fit is Regulatory Filings (RNS) as a general announcement category for miscellaneous filings that do not fit other specific categories.
2018-07-05 Chinese
关于使用部分闲置自有资金和募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Zhuhai Jianfan Biotechnology Co., Ltd. regarding the use of idle self-owned funds and raised funds for cash management investments. It details specific purchases of structured deposits and wealth management products, including amounts, terms, expected yields, and risk management measures. The document references prior shareholder meeting resolutions approving the use of funds for cash management and includes a summary table of investment products purchased in the past twelve months. The document is an announcement of financing and investment activities related to the company's capital management rather than a full financial report or earnings release. It does not contain comprehensive financial statements or quarterly results but focuses on capital usage and investment updates. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (6421 characters) supports it being a detailed announcement rather than a brief notice or a full annual/interim report.
2018-07-05 Chinese
关于使用部分闲置自有资金和募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Zhuhai Jianfan Biotechnology Co., Ltd. regarding the use of idle self-owned funds and raised funds for cash management, including specific purchases of financial products, risk assessments, and impact on the company. It references prior shareholder meeting resolutions and provides detailed financial product information and investment terms. The document is not a full financial report like an Annual Report or Interim Report, nor is it a simple announcement of a report publication. It is a regulatory announcement about capital management activities and investment of funds, which fits best under Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive financial investment details, not just a brief notice or certification. Therefore, the classification is CAP with high confidence.
2018-07-04 Chinese
2018年半年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2018 half-year performance forecast (业绩预告) for the period January 1 to June 30, 2018. It provides estimated net profit growth percentages and reasons for performance changes but explicitly states that the forecast is preliminary, unaudited, and that detailed financial data will be disclosed in the 2018 half-year report. The document is short (754 characters) and serves as an earnings preview rather than a full financial report. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. H1 2018
2018-07-02 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.